Questcor Pharmaceuticals (QCOR), a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome and infantile spasms indications. Its products include H.P. Acthar Gel and Doral. This stock is trading up 3.7% at $33.90 in recent trading.
Today's Volume: 4.18 million
Average Volume: 1.62 millionVolume % Change: 323% Shares of QCOR are ripping higher today after the company said its net income nearly doubled in the fourth quarter on an increase in prescriptions of its H.P. Acthar Gel, which is used to treat several autoimmune and inflammatory diseases. >>5 Stocks Set to Soar on Bullish Earnings From a technical perspective, QCOR is trending up here and moving back above its 200-day moving average of $33.87 with heavy upside volume. This stock has been uptrending strong since it cleared its 50-day at $27.54 a few weeks ago, with shares soaring to its intraday high of $34.74. During that uptrend, shares of QCOR have been consistently making higher lows and higher highs, which is bullish technical price action. Traders should now look for long-biased trades in QCOR as long as it's trending above today's low of $31.50 or above its 200-day at $33.87 with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 1.62 million shares as bullish. If QCOR can maintain that trend, then this stock will set up to trend well north of $40 a share. In fact, the next major resistance level for QCOR sits at $50. Jazz Pharmaceuticals Jazz Pharmaceuticals (JAZZ - Get Report) is a specialty pharmaceutical company focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. This stock is trading up 3.1% at $58.62 in recent trading. Today's Volume: 886,000 Average Volume: 472,361 Volume % Change: 203% Shares of JAZZ are moving higher today after the company reported that fourth-quarter revenue surged due to acquisitions and sales growth for its narcolepsy treatment Xyrem. From a technical perspective, JAZZ is spiking higher here right off its 50-day moving average of $55.76 with above-average volume. This move has started to push shares of JAZZ into breakout territory, since the stock has flirted with some near-term overhead resistance levels at $57.70 to $59.19. At last check, JAZZ has hit an intraday high of $59.89 and volume is well above its three-month average action of 472,361 shares.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts